Clinical Trial Update: Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy [Phase 2]

View source ↗

Summary

A Phase 2 dose-escalation safety study evaluating ISIS 301012 in patients with familial hypercholesterolemia on lipid-lowering therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia

Drugs mentioned

• ISIS 301012 (antisense oligonucleotide targeting apolipoprotein B-100)

Snippet

Sponsor: Kastle Therapeutics, LLC | Conditions: Hypercholesterolemia, Familial | Phase 2 | Status: COMPLETED